Avian myogenesis is partly characterized by commitment of distinct myoblast cell lineages to the formation of specific muscle fiber types. Previous studies have identified the transcription factor EMX2 as a regulator of slow myosin heavy chain 2 (MyHC2) gene expression in fast/slow primary muscle fibers. We report here the interaction of EMX2 with the slow MyHC2 transcriptional regulatory region in fast/slow embryonic muscle fibers. Promoter activity and electromobility shift assays localized the site of interaction of EMX2 with the slow MyHC2 gene within a defined binding site located between 3336 and 3326 bp from the 3′ end of the cloned slow MyHC2 DNA containing the transcriptional regulatory region. Using clonally-derived myoblasts stably committed to the formation of fast/slow muscle fibers, we also report the effect of altered EMX2 gene expression on genome-wide gene expression within these myoblasts. Increased EMX2 gene expression in fast/slow myoblasts caused altered gene expression of 1185 genes, indicating that EMX2 plays a central role in the gene expression profile of embryonic myoblasts.
Introduction
Vertebrate myogenesis is characterized by multiple distinct stages of myogenic cell proliferation and differentiation, and each stage is defined by specific myogenic cell types and differentiated muscle fiber types. The early, embryonic stage includes somitogenesis from paraxial mesoderm and formation of primary muscle fibers from embryonic myoblasts. The fetal phase of myogenesis is characterized by expansive proliferation of secondary, fetal myoblasts which differentiate into secondary muscle fibers. Lastly, adult myogenesis is defined by the appearance of muscle satellite cells and their contribution to growth and tissue regeneration. In avian species, these stages occur approximately during embryonic days 3-8, 9-18, and 18 to adulthood, respectively (Stockdale, 1992) .
Embryonic and fetal myoblasts are distinct cell populations. The two cell types have different media requirements for growth and differentiation in vitro (Seed and Hauschka, 1988) . Differentiation of embryonic, but not fetal, myoblasts is inhibited by the phorbol ester, 12-Otetradecanoyl phorbol 13-acetate (TPA), and β-catenin signaling is required for embryonic, but not fetal, myoblast differentiation (Cossu et al., 1988; Messina and Cossu, 2009 ). In addition, whereas embryonic myoblasts have an elongated cell morphology and differentiate into mononucleated or oligonucleated myotubes, fetal myoblasts do not typically have long cell projections and fuse into large multinucleated myotubes (Biressi et al., 2007a) . Moreover, genome-wide gene expression analysis revealed multiple genes, including Hox genes, that are differentially expressed between embryonic and fetal myoblasts and that reflect intrinsically different myogenic cell lineages (Biressi et al., 2007b) .
In addition to phenotypic differences between embryonic and fetal myoblasts, each stage of myogenesis is characterized by the existence of distinct myogenic cell types. The avian embryonic myoblast population is comprised of at least three distinct myogenic cell lineages. These lineages are defined by the inherent and stable capacity to form different muscle fiber types -fast, fast/slow, and slow -both in vitro and in vivo. The distinct myoblast lineage properties during embryonic myogenesis are independent of innervation Stockdale, 1986a, 1986b; DiMario et al., 1993) . Similar to embryonic myogenesis, the fetal population of myoblasts is also comprised of different myoblast cell types that specifically form different muscle fiber types. However, the distinction in differentiation potential of these fetal myoblasts types is elicited by innervation or electrical stimulation (DiMario and Stockdale, 1997; Jiang et al., 2004; Crew et al., 2010) .
Based on these distinct myoblast types throughout development, it is readily evident that differences in muscle fiber types also exist throughout embryonic, fetal, and adult myogenesis. Avian skeletal muscle fibers are categorized as fast, fast/slow, or slow based on expression of genes that encode fast and slow myosin heavy chain (MyHC) isoforms. Expression of the slow MyHC2 gene occurs throughout all three developmental stages of myogenesis (embryonic, fetal, adult) and is, in large part, responsible for the slow muscle fiber type contractile Mechanisms of Development 147 (2017) 
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properties in adult slow muscle Stockdale, 1986a, 1986b; Kennedy et al., 1986) . A number of molecular pathways and regulatory proteins have been identified as regulators of skeletal muscle fiber type. For example, the Nuclear Factor of Activated T cells (NFAT) is a target of calcineurin, a calcium/calmodulin dependent protein phosphatase that controls NFAT phosphorylation status, nuclear localization, and subsequent transcriptional activation of a subset of contractile protein genes (Chin et al., 1998) . Another factor, PGC-1α, enhances the slow muscle fiber phenotype through mitochondrial biogenesis and increased oxidative metabolic capacity in exercised mice (Nandschin et al., 2007) . In contrast, other factors such as Sox6 repress development of the slow muscle fiber phenotype as demonstrated by increased slow muscle fibers in Sox6-deficient animals (Hagiwara et al., 2007) . Also, other factors regulate the fast muscle fiber phenotype. Six1/Six4 proteins drive development of fetal fast muscle fibers by regulating a variety of genes associated with fast muscle fibers, particularly genes involved in fast muscle fiber calcium homeostasis (Richard et al., 2011) .
It is important to recognize that the majority of studies on regulators of muscle fiber phenotype focus on fetal and adult muscle fibers which are primarily derived from fetal myoblasts. Based on the knowledge that embryonic and fetal myoblasts are distinct, have different myogenic cell lineages within each embryonic and fetal myoblast population, and give rise to distinct muscle fibers with varying responses to external stimuli such as innervation, it is reasonable to hypothesize that the transcriptional mechanisms that control muscle fiber type development differ between embryonic and fetal muscle fibers. Such is the case for transcriptional regulation of the slow MyHC2 gene in embryonic and fetal avian muscle development. Promoter analysis in embryonic fast/ slow muscle fibers indicated that NFAT binding sites did not activate slow MyHC2 gene transcription. Indeed, one NFAT binding site demonstrated transcriptional repressor activity. Also, MEF2 activated the slow MyHC2 promoter, but in a non-fiber type specific manner (Theobald and DiMario, 2011) . In contrast, the MEF2 and NFAT binding sites as well as an E-box activated slow MyHC2 gene transcription in a slow fiber type specific manner (Jiang et al., 2004) . The results of these studies emphasize that embryonic and fetal muscle fiber type development and slow MyHC2 gene expression are controlled by different cellular and molecular mechanisms.
The EMX2 gene is a vertebrate orthologue of Drosophila empty spiracles (ems), a homeobox gene that controls anterior head development, embryonic brain segmentation, and posterior spiracle formation (Dalton et al., 1989; Walldorf and Gehring, 1992; Cohen and Jürgens, 1990; Hirth et al., 1995) . In vertebrates, the EMX2 gene is expressed in a variety of ectodermally and mesodermally derived tissues. It is expressed in the developing cerebral cortex and olfactory bulb (Simeone et al., 1992) . EMX2 gene expression within the adult telencephalon regulates the frequency of symmetric divisions and homeostasis of stem cells (Galli et al., 2002) . It is also required for normal cell proliferation and differentiation of sensory precursor cells involved in ear development and normal auditory sensorineural conduction (Rhodes et al., 2003; Holley et al., 2010) . EMX2 gene expression is also required for normal metanephrogenesis as evidenced by defects in ureteric bud morphogenesis in EMX2 mutant mice (Miyamoto et al., 1997) . EMX2 gene expression is decreased in premenopausal endometrium relative to postmenopausal endometrium and is reduced in primary endometrial tumors (Noonan et al., 2001) . Normal skeletal development is also dependent on EMX2 gene expression. Positional information that contributes to specificity of skeletal elements within the developing scapula and ilium is dependent on normal EMX2 gene expression (Pröls et al., 2004; Malashichev et al., 2008) . In both kidney and scapula development, EMX2 gene expression appears to be controlled by β-catenin signaling. Loss-of-function β-catenin mutants resulted in reduced EMX2 gene expression and defects in ureteric bud morphogenesis and scapula formation (Bridgewater et al., 2008) . Gain-of-function β-catenin mutants increased EMX2 gene expression (Hill et al., 2006) .
Previous genome-wide expression analysis identified EMX2 as a gene differentially expressed in the embryonic fast/slow myogenic lineage and as a positive transcriptional regulator of the slow MyHC2 gene in fast/slow embryonic muscle fibers (Weimer et al., 2013) . In this study, we report the mechanism by which EMX2 controls embryonic muscle fiber type development through transcriptional regulation of the slow MyHC2 gene in the fast/slow embryonic myogenic cell lineage.
Materials and methods

Cell culture
Embryonic myoblasts within the fast/slow myogenic lineage were derived as previously described (Theobald and DiMario, 2011 ). Cells were grown in 100 mm collagen-coated dishes containing medium comprised of 10% horse serum (Hyclone), 5% chick embryo extract, 1.32 mM CaCl 2 , 2 mM glutamine, 1× antibiotic/antimycotic (Life Technologies) in Ham's F-10 basal medium (Sigma) mixed in equal volume with the same medium conditioned by incubation with differentiated ED13 fetal chicken myotubes for 2 days (Miller and Stockdale, 1986a) .
Transfection and transduction
Embryonic myoblasts were re-plated into 35 mm cell culture plates prior to transfection. Generation of the full-length 6150SM2Luc promoter-luciferase DNA construct containing 5229 bp of slow MyHC2 DNA upstream from exon 1 and 921 bp of downstream sequence was previously described (Theobald and DiMario, 2011) . Slow MyHC2 promoterfirefly luciferase reporter DNA (3 μg) and pRLSV40 DNA (1 μg) encoding Renilla luciferase were transfected into fast/slow myoblasts using Lipofectamine 2000 (Promega) for 5 h at 37°C in a 5% CO 2 humidified incubator. For some experiments, 1 μg of pCMVEMX2 or the control pCMVTAG vector (Stratagene) were co-transfected.
For viral transduction, full length EMX2 cDNA with GFP linked to the 3′ end was cloned into pLenti6/V5-Dest lentiviral vector (Invitrogen) for constitutive expression from the CMV promoter. Embryonic myoblasts were transduced with EMX2GFP lentiviral particles for 24 h when myoblasts had reached approximately 50% confluency after approximately 2 days in culture. A control lentiviral vector containing GFP cDNA was also introduced into separate embryonic myoblast cultures. Transduced myoblasts were passaged to prevent myoblast fusion and maintain myoblasts in an undifferentiated state.
Luciferase assays
Transfected myoblasts were allowed to differentiate for 5 days prior to measurement of promoter activities. Differentiated myotubes were processed and luciferase activities were measured using the Dual-Glo Luciferase Assay (Promega) according to manufacturer's instructions. Variation in transfection efficiencies across experiments and between slow MyHC2 promoter/pRLSV40 mixtures were normalized to Renilla luciferase activity. Promoter activities were compared using Student's t-test with p values b 0.05 established as statistically significant.
Electromobility shift assays
Preparation of nuclear protein extracts from embryonic myoblasts was based on previously published methods (Dignam et al., 1983) . Cells were washed with cold phosphate buffered saline (PBS) and scraped into microcentrifuge tubes using cold PBS. Cells were then pelleted in an Eppendorf centrifuge at 2000 rpm for 4 min at 4°C. Pellets were resuspended in 400 μl of 10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, plus protease inhibitors and incubated on ice for 10 min. NP-40 (10 μl) was added to the cell suspension which was then vortexed vigorously. The suspension was centrifuged at 6000 rpm for 4 min at 4°C, and the nuclear pellet was resuspended in 20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM DTT plus protease inhibitors. The suspension was vortexed frequently while incubating on ice for 15 min. The suspension was centrifuged at 14,000 rpm for 5 min at 4°C, and the supernatant was collected. Protein content was determined using a protein assay kit (Bio-Rad).
Doublestranded oligonucleotides were end-labeled with 32 P-ATP.
The following binding reactions were incubated at room temperature for 20 min: 4 μl of binding buffer (75 mM HEPES, pH 7.9, 200 mM KCl, 5 mM EDTA, 2.5 mM DTT, 25 mM MgCl 2 , 25% glycerol), 2 μl of 10 mM poly dI-dC, 1 μl of 6 μg/μl BSA, 10μg of nuclear protein extract, and water to total volume of 20 μl. Labeled oligonucleotide (100,000 cpm in 1 μl) was then added and incubated on ice for 20 min. In some reactions, 100-fold molar excess of unlabeled oligonucleotides were added as competitors of protein-DNA complex formation. For electromobility supershift assays, the following doublestranded oligonucleotide was used as the DNA probe: 5′-CACGGAGAGTAATTCTCCTTCC-3′. Some of these reactions contained 4 μg of an anti-EMX2 antibody (Vendor) or a non-specific mouse IgG antibody. Protein-DNA complexes were resolved by electrophoresis in a 5% nondenaturing polyacrylamide gel and visualized by exposure to X-ray film overnight at −80°C.
RNA-Seq
mRNA was purified from myoblasts transduced with lentiviral vectors and expressing CMVGFP and CMVEMX2 cDNAs. RNA-seq methodologies and initial analyses were conducted by LC Sciences using Illumina 2000 and 2 × 100 bp paired-end sequencing. GO annotations are based on UniProtBlast, Entrez Gene, and Expasy Proteomic databases. Differential gene expression due to EMX2 gene expression was assessed through average reads of multiple RNA samples and normalization of GFP cDNA expression. Genes differentially expressed by at least 2-fold are included in the reported analysis.
QRT-PCR
cDNA synthesis from RNA samples derived from embryonic myoblasts transduced with CMVGFP or CMVEMX2 was primed with oligodT and random hexamers. Amplification was performed in triplicate using qRT-PCR SYBR Green master mix including ROX passive reference dye (Applied Biosystems). Two reference genes, GAPDH and RPLO, were used for normalization of amplification variability across samples. Expression levels of each gene, calculated by determination of ΔΔCT, were compared between myoblasts expressing CMVGFP and CMVEMX2. Oligonucleotides used for amplification are listed in Supplement Table 1 .
Results
Slow MyHC2 promoter regulation by EMX2
We have previously shown that EMX2 gene expression increased slow MyHC2 promoter activity in myotubes derived from the embryonic fast/slow myoblast lineage and that this activation was lineage-specific. EMX2 gene expression did not significantly increase slow MyHC2 gene expression in the embryonic fast myogenic cell lineage (Weimer et al., 2013) . To determine the region of the slow MyHC2 promoter that conferred EMX2-mediated transcriptional activation, a series of promoter deletions, linked to the luciferase reporter gene, was generated in addition to the full length 6150 bp wild type slow MyHC2 promoter. The deletions contained 3412 bp, 3242 bp, and 2279 bp of slow MyHC2 DNA sequence from the 3′ end of the parent full length construct. These DNA constructs were co-transfected with either the pCMVEMX2 expression construct or the empty pCMVTAG vector DNA. Transfected myoblasts were allowed to differentiate for 5 days, and promoter activities were then measured (Fig. 1) . EMX2 gene expression activated the full length 6150 bp and 3412 bp slow MyHC2 promoters by 96.6 ± 16.9% and 88.5 ± 11.3%, respectively. However, EMX2 gene expression did not activate the 3242 bp or 2279 bp slow MyHC2 promoters. Rather, the activities of these promoters were modestly repressed by 19.8 ± 10.6% and 21.4 ± 7.1%, respectively. Deletion of the promoter segment between 3412 bp and 3242 bp abrogated the ability of EMX2 gene expression to activate the slow MyHC2 promoter in embryonic fast/slow myotubes.
To determine whether the promoter segment between 3412 and 3242 bp interacted with a component of nuclear protein extract from embryonic fast/slow myotubes, five oligonucleotides that span the promoter segment with 10 bp overlaps were incubated with nuclear extract ( Fig. 2A) . Formation of protein-DNA complexes was determined by resolution in a non-denaturing polyacrylamide gel (Fig. 2B) . The only oligonucleotide that formed a protein-DNA complex contained sequence between 3348 and 3306 bp.
To more precisely identify the slow MyHC2 promoter sequence that interacted with the nuclear extract, mutations were introduced into the oligonucleotide containing the 3348-3306 bp sequence. To span the length of the wild type sequence, 8 bp substitutions were introduced into a cohort of 5 oligonucleotides (Fig. 3A) . These mutated Fig. 1 . Fast/slow embryonic myoblasts were transfected with slow MyHC2 promoter-luciferase constructs containing 6150 bp, 3412 bp, 3242 bp, and 2279 bp of slow MyHC2 regulatory DNA sequence with co-transfection of either pCMVEMX2 or control pCMVTAG expression constructs. The DNA construct is shown diagrammatically and not to scale. Each construct contains the Luciferase gene coding sequence (Luc), the entire first exon (E1) and the 5′ portion of exon 2 (E2) of the slow MyHC2 gene. Also shown are transcription regulatory sites: TATA box , E-box , CEBP , MEF2 , NFAT . Myoblasts were allowed to differentiate, and promoter activities were then measured. Bars represent relative promoter activation (±S.D.) in cells transfected with the slow MyHC2 promoter-reporter plus pCMVEMX2 versus the slow MyHC2 promoter-reporter plus pCMVTAG (n = 5, *p b 0.01).
oligonucleotides were used as competitors for binding of nuclear extract proteins from embryonic myotubes with the wild type 3348-3306 bp oligonucleotide in electromobility shift assays (Fig. 3B) . Oligonucleotides 1 and 2, containing 8 bp substitutions each at the 5′ end of the 3348-3306 bp segment, effectively competed for protein-DNA complex formation with the wild type oligonucleotide. Similarly, oligonucleotide 5, which has an 8 bp substitution at the 3′ end of the 3348-3306 bp segment, effectively competed for complex formation. However, oligonucleotides 3 and 4 did not effectively compete against the wild type oligonucleotide for protein-DNA complex formation. These results indicate that protein-DNA complex formation with the wild type oligonucleotide occurs via the sequence mutated in oligonucleotides 3 and 4.
Analysis of the 3348-3306 bp DNA sequence via the ALGGEN-PROMO server (Farré et al., 2003) identified a candidate homeobox domain protein binding site at 3336-3326 bp (Fig. 3A) . This candidate binding site, GAGTAATTCTC, was mutated in the oligonucleotides 2 and 3 that did not effectively compete for protein-DNA complex formation against the wild type oligonucleotide. To determine whether EMX2 is a protein component of the protein-DNA complex formed by the myotube nuclear extract and slow MyHC2 DNA sequence, another electromobility shift assay was performed with a more narrowly designed oligonucleotide probe, focusing on the homeobox binding sequence, as well as an anti-EMX2 antibody (Fig. 4) . Incubation of the oligonucleotide probe with nuclear extract from fast/slow myotubes yielded a shifted protein-DNA complex. The variation in banding profile of the shifted complex from previously shown shifted complexes is likely due to the use of a different oligonucleotide probe focused on the homeobox domain binding site. Inclusion of an anti-EMX2 antibody yielded an additional shift of the protein-DNA complex, not evident when a control non-specific antibody was included in the reaction.
Transcriptome analysis of cells expressing the EMX2 gene
To further understand the transcriptome-wide effect of EMX2 gene expression in embryonic myoblasts, mRNA was isolated from myoblasts infected with CMVEMX2 or CMVGFP-expressing lentiviral vectors. RNASeq results indicated that EMX2 was the gene that had the highest differential expression, and was the most highly expressed gene, which served a positive internal control. Sequence analysis produced 1185 unique hits with a value of two-fold or greater changes in differential gene expression. The identification of this sub-set of genes utilized the basic alignment search tool UniProtBLAST and the Entrez Gene and Expasy Proteomics Servers to assign GO annotation (Fig. 5) . The subgroups of genes defined by gene ontology were adhesion, apoptosis, cell cycle, cell trafficking, cytoskeleton, DNA-binding, ECM, metabolism, RNA-binding, signaling, structural, transcription.
Of the 1185 genes differentially expressed in cultures of fast/slow myoblasts infected with the CMVEMX2 lentivirus, 62.89% of these genes were upregulated, and 37.11% of the genes were downregulated.
The percentage of known genes assigned to the adhesion and cell cycle functions was 2.4% and 4.1%, respectively (Supplement Tables 2 and 3) . Known cytoskeleton genes comprised 2.1% of the differentially expressed genes (Supplement Table 4 ). DNA-binding and genes that encode components of extracellular matrix were 6.9% and 1.9%, respectively, of the total genes (Supplement Table 5 and Table 6 ). Genes associated with metabolism made up the largest category at 25.2% of known differentially expressed genes (Supplement Table 7 ). Of note, the gene encoding Mammalian Target of Rapamycin (mTOR) was upregulated 7.47 fold. RNA-binding accounted for 17.9% of total differentially regulated genes between fast/slow myoblasts and fast/slow myoblasts overexpressing EMX2 (Supplement Table 8 ). Within this functional category, Fragile X Mental Retardation 1 (FMR1) was selected as a gene of interest. The FMR1 gene encodes an RNA-binding protein that was up-regulated 2.43 fold upon EMX2 overexpression. FMR1 plays a role in intracellular RNA transport, regulation of translation of target mRNAs, and acts as a transcriptional repressor (Li et al., 2001; Laggerbauer et al., 2001; Zalfa et al., 2003) .
Genes associated with cell signaling accounted for 18.7% of total genes differentially regulated between fast/slow myoblasts and fast/ slow myoblasts overexpressing EMX2 (Supplement Table 9 ). Within this functional category, Frizzled Class Receptor 7 (FZD7) and Wnt1 Inducible Signaling Pathway 1 (WISP1) were selected as genes of interest. The FZD7 gene encodes a transmembrane receptor for Wnt signaling proteins (Katoh, 2008) , and its expression was downregulated 2.81 fold upon EMX2 overexpression. WISP1, a Wnt signaling protein, is a downstream regulator in the Wnt/Frizzled-signaling pathway (Pennica et al., 1998) . WISP1 is associated with cell survival, as it attenuates p53-mediated apoptosis in response to DNA damage through activation of AKT kinase (Colston et al., 2007; Reddy et al., 2011; Su et al., 2002; Venkatesan et al., 2010) . WISP1 gene expression was upregulated 11.28 fold upon EMX2 overexpression. Structural and trafficking genes comprised 10.0% and 6.4%, respectively, of the known differentially expressed genes (Supplement Table 10 and Table 11 ). Expression of the trafficking gene myoferlin (MYOF) was of particular interest for further validation as it was downregulated 4.08 fold upon EMX2 overexpression. The MYOF gene encodes the calcium/phospholipid-binding protein myoferlin that plays a role in the plasmalemma repair mechanism for rapid resealing of membranes disrupted by mechanical stress (Bansal et al., 2003; Bansal and Campbell, 2004) . Genes encoding transcriptional regulators accounted for 8.5% of differentially expressed genes (Supplement Table 12 ). Several genes of interest within the functional category of transcription are noted. Nuclear factor of activated Tcells calcineurin-dependent, cytoplasmic 3 (NFATC3) was 7.97 fold downregulated. General transcription factor IIH polypeptide 3 (GTF2H3) gene expression was downregulated 5.64 fold. GLI family zinc finger 1 (GLI1) and peroxisome proliferator-activated receptorgamma coactivator 1-alpha (PGC1α) gene expression was upregulated 8.61 and 7.64 fold, respectively (Fig. 6) .
qRT-PCR analysis validated the differential expression of a number of genes cited above (Table 1) . RNA-Seq data indicated that EMX2 gene expression activated genes encoding GLI1, WISP1, PGC1α, and mTOR. qRT-PCR analysis validated the upregulation of genes encoding GLI1 and WISP1. qRT-PCR analysis of PGC1α and mTOR was not performed. RNA-Seq data had indicated that EMX2 gene expression repressed genes encoding FMR1, FZD7, MYOF, GTF2H3, and NFATC3. qRT-PCR analysis validated the downregulation of genes encoding FMR1, FZD7, MYOF, and GTF2H3. This analysis did not validate the downregulation of NFATC3.
Discussion
Avian myogenesis is partly characterized by myogenic cell commitment to the formation of distinct muscle fiber types. During embryonic skeletal muscle development, myoblast cell lineages appear that are committed to the formation of fast and fast/slow primary muscle fibers. A distinguishing feature of fast versus fast/slow muscle fibers is expression of the slow MyHC2 gene in the latter. Previous studies have shown that slow MyHC2 gene expression is transcriptionally controlled by different regulatory mechanisms in embryonic versus fetal muscle fibers and that its expression in embryonic fast/slow muscle fibers is controlled by a transcriptional regulatory element(s) in the promoter region upstream from the regulatory sites that control its transcription in fetal muscle fibers (Theobald and DiMario, 2011) . Previous studies have also indicated that the EMX2 transcriptional regulator increases slow MyHc2 gene expression and that the EMX2 gene is expressed in fast/slow muscle and myoblasts committed to the fast/slow myogenic cell lineage, but not the fast myogenic cell lineage (Weimer et al., 2013) .
The current study demonstrates that EMX2 binds to a specific DNA element within the upstream slow MyHC2 promoter region. Deletion analysis of the slow MyHC2 promoter initially placed the location of the binding site within a 170 bp DNA segment. Electromobility shift assays using wild type and mutated oligonucleotides further delineated the binding site within a 42 bp fragment. Interaction of EMX2 with the DNA binding site was verified using an EMX2-specific antibody.
These results are significant in that the binding site for EMX2 in its regulation of the slow MyHC2 gene has been identified. In addition, and importantly, EMX2 is a homeodomain protein and a member of a class of transcriptional regulators that contribute to cell fate determination (Simeone et al., 1992; Walldorf and Gehring, 1992) . As such, EMX2 may exhibit this function in the regulation of fiber type determination in embryonic avian myogenesis since it upregulates expression of the slow Fig. 5 . Relative distribution of genes differentially expressed in fast/slow myoblasts. Genes expressed more than two-fold in fast/slow myoblasts were included in the analysis. Gene functions were assigned by GO annotation and Entrez Gene and Expasy Proteomic Servers. Pie chart presents the percentages of genes assigned functional categories (refer to color legend) for the genes that were differentially expressed in fast/slow myoblasts (1185 total genes) from multiple myogenic clones. MyHC2 gene in differentiated fast/slow muscle fibers and is expressed in the myoblasts that form these fibers (Weimer et al., 2013) . Some parallels of EMX2 function in regulation of fast/slow muscle fiber development may exist with transcription factor Six1 function and regulation of the fast muscle fiber type specific genes in mouse development. Six 1 is also a homeobox protein that regulates expression of fast MyHC genes in fast muscle fibers (Richard et al., 2011) . Both Six1 and EMX2 may regulate MyHC gene expression by control of chromatin conformation at the respective MyHC loci. The distant upstream location of EMX2 interaction with the slow MyHC2 transcriptional regulatory region further suggests that EMX2 may not directly upregulate slow MyHC2 gene transcription, but alter the chromatin landscape for increased transcription to occur. Additional studies are needed to determine if these proteins control MyHC gene expression by such mechanisms.
EMX2 may also control expression of other downstream genes that regulate transcription and muscle fiber type. Toward that end, we report the results of differential gene expression in response to overexpression of the EMX2 gene in embryonic fast/slow myoblasts. RNAseq analysis indicated that EMX2 gene expression was increased approximately 18 fold. As anticipated, changes in gene expression occurred in a variety of functional groups. Genes involved in cell metabolism, signaling, and RNA binding collectively comprised the majority (approximately 62%) of differentially expressed genes. Also, genes encoding DNA binding proteins/transcriptional regulators accounted for approximately 15% of identified genes. Genes of particular interest that affect skeletal muscle development and which were differentially expressed according to qRT-PCR and/or RNA-Seq analyses included NFAT, PGC1α, mTOR, GLI1, GTF2H3, FMR1 and FZD7. The lack of validation of NFATC3 in RNA-seq and QRT-PCR analyses may be due to the existence of at least two NFATC3 transcript variants. The relative expression of these mRNA transcripts is not known in our clonal cell populations used for RNA-seq analysis. RNA-seq and QRT-PCR analyses may have preferentially detected different NFATC3 transcripts. Therefore EMX2 may increase slow MyHC2 gene transcription directly by recruitment of transcriptional machinery, indirectly by altering chromatin conformation, and/or indirectly by transcription of other regulatory genes that then control slow MyHC2 gene expression. This experimental system is amenable to continued elucidation of such possible regulatory mechanisms.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.mod.2017.06.006.
